Anti-Ro/SSA Antibodies Are an Independent Factor Associated with an Insufficient Response to Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

Matsudaira, Ran; Tamura, Naoto; Sekiya, Fumio; Ogasawara, Michihiro; Yamanaka, Kenjiro; Takasaki, Yoshinari

doi:10.3899/jrheum.101295

Cited by 26 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a recent study showed that RA patients with secondary SS developed more severe arthritis and higher RA disease activity than those without secondary SS [26]. Another study showed that the presence of anti-SS-A antibody and secondary SS in patients with RA could lower clinical response to TNF inhibitors [27]. The latter study reported that the EULAR responder (good or moderate) rate in RA patients with secondary SS or anti-SS-A antibody was significantly lower (63% in secondary SS and 58% in anti-SS-A antibody-positive patients) than in those without secondary SS or anti-SS-A antibody (82% and 83%, respectively) [27].…”

Section: Discussionmentioning

confidence: 99%

“…Another study showed that the presence of anti-SS-A antibody and secondary SS in patients with RA could lower clinical response to TNF inhibitors [27]. The latter study reported that the EULAR responder (good or moderate) rate in RA patients with secondary SS or anti-SS-A antibody was significantly lower (63% in secondary SS and 58% in anti-SS-A antibody-positive patients) than in those without secondary SS or anti-SS-A antibody (82% and 83%, respectively) [27]. In the present study, we demonstrated that abatacept was effective even for RA involvement in most (82.9%) patients with RA and secondary SS who were positive for anti-SS-A antibody with a high adherence rate for 52 weeks, though such patients are considered to have severe disease and are often resistant to TNF inhibitors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

Tsuboi

Matsumoto

Hagiwara

et al. 2016

Modern Rheumatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

Tsuboi

Matsumoto

Hagiwara

et al. 2016

Modern Rheumatology

View full text Add to dashboard Cite

“…Some authors also have mentioned a strong association between anti-Ro antibodies and the development of side effects by treatment with gold salts or D-penicillamine [144–146]. In a recent report anti-Ro antibodies are suggested to be an independent factor associated with an insufficient response to tumor necrosis factor (TNF) inhibitors in patients with RA [147]. …”

Section: Anti-ro Antibodies and Autoimmune Diseasesmentioning

confidence: 99%

Clinical and Pathological Roles of Ro/SSA Autoantibody System

Yoshimi

Ueda

Ozato³

et al. 2012

Clinical and Developmental Immunology

114

View full text Add to dashboard Cite

Anti-Ro/SSA antibodies are among the most frequently detected autoantibodies against extractable nuclear antigens and have been associated with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Although the presence of these autoantibodies is one of the criteria for the diagnosis and classification of SS, they are also sometimes seen in other systemic autoimmune diseases. In the last few decades, the knowledge of the prevalence of anti-Ro/SSA antibodies in various autoimmune diseases and symptoms has been expanded, and the clinical importance of these antibodies is increasing. Nonetheless, the pathological role of the antibodies is still poorly understood. In this paper, we summarize the milestones of the anti-Ro/SSA autoantibody system and provide new insights into the association between the autoantibodies and the pathogenesis of autoimmune diseases.

show abstract

“…Anti-SSA/Ro mainly targets the autoantigen Ro52 (41). However, as with many mediators involved in this disease, the precise role of these autoantibodies in the pathogenesis of this condition is not clearly understood.…”

Section: Resultsmentioning

confidence: 99%

Sjogren's syndrome: Review of the aetiology, Pathophysiology a Potential therapeutic interventions

Nair¹,

Singh²

2017

J Clin Exp Dent

View full text Add to dashboard Cite

BackgroundSjogren’s syndrome (SS) is an autoimmune disorder characterised by lymphocytic infiltration of exocrine glands, resulting in glandular dysfunction. Objectives: This study aims to review the aetiology of Sjogren’s syndrome, highlight aspects that contribute to the pathophysiology of the disease and explore treatment options that target different mediators of pathogenesis.Material and MethodsThe MEDLINE/PubMed and Google Scholar databases were searched systematically with the terms “Sjogren’s syndrome”; “clinical”; “treatment”; “management”. Eligible studies had to meet a predefined inclusion criteria.Results912 identified studies were evaluated against the inclusion criteria. 25 eligible studies were included for review. Sjogren’s syndrome is a multifactorial condition with genetic, environmental and hormonal factors playing a role in establishing the condition. B-cell activating factor (BAFF) is an important mediator in the induction and perpetuation of this condition. Elevated BAFF levels, found in patients with SS, promote growth of B-cells and subsequent production of autoantibody; anti-SSA/Ro. BAFF inhibitors are important potential therapeutic drugs that may be effective in patients with Sjogren’s syndrome. Other potential targets include CD20 and CD22 that cause B-cell depletion.ConclusionsThe pathophysiology of this exocrinopathy has not fully been elucidated. Potential therapeutic interventions include BAFF inhibitors and anti-CD20 and anti-CD22 therapy. However, no clinical trials have been conducted on subjects with Sjogren’s syndrome to support existing research. Key words:Sjogren’s syndrome, autoimmune, rheumatology.

show abstract

Anti-Ro/SSA Antibodies Are an Independent Factor Associated with an Insufficient Response to Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

Abstract: The presence of anti-Ro might be related to the lesser clinical response to infliximab compared to other TNF inhibitors, suggesting that the presence of anti-Ro should be considered when choosing the appropriate biologics for patients with RA.

Cited by 26 publications

References 28 publications

Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial

Clinical and Pathological Roles of Ro/SSA Autoantibody System

Sjogren's syndrome: Review of the aetiology, Pathophysiology a Potential therapeutic interventions

Contact Info

Product

Resources

About